Replimune(US:REPL) Globenewswireยท2025-10-19 12:00Core Insights - Replimune Group, Inc. presented new data from the IGNYTE phase 2 cohort of RP1 plus nivolumab at the ESMO Congress 2025, highlighting promising results for acral melanoma patients [1][2] Group 1: Clinical Trial Results - The analysis showed an objective response rate of 44% (8 out of 18 patients) for acral melanoma patients treated with RP1 and nivolumab, with a median duration of response of 11.9 months [2] - The safety profile of the treatment was favorable, with mostly transient grade 1 and 2 treatment-related adverse events [2] Group 2: Background on Acral Melanoma - Acral melanoma is a rare and aggressive form of cutaneous melanoma, accounting for 2-3% of all melanoma cases, often presenting poor outcomes and limited treatment options [3] - Current therapies, including immune checkpoint inhibitors, typically do not yield effective results for acral melanoma, especially after progression on first-line therapy [3] Group 3: Ongoing and Future Trials - The IGNYTE-3 phase 3 trial is currently recruiting participants to evaluate RP1 plus nivolumab against physician's choice of treatment for melanoma that has progressed on anti-PD1 and anti-CTLA-4 therapy [4] - An additional poster on the efficacy and safety of RP1 plus nivolumab in non-melanoma skin cancers is also being presented at the ESMO Congress [4] Group 4: About RP1 - RP1 (vusolimogene oderparepvec) is Replimune's lead product candidate, engineered from a proprietary strain of herpes simplex virus, designed to enhance tumor killing and activate systemic anti-tumor immune responses [6] Group 5: Company Overview - Replimune Group, Inc., founded in 2015 and headquartered in Woburn, MA, aims to transform cancer treatment through innovative oncolytic immunotherapies [7] - The company's RPx platform is based on a potent HSV-1 backbone, intended to maximize immunogenic cell death and induce a systemic anti-tumor immune response [7]